葛兰心宁软胶囊治疗冠心病心绞痛的临床效果及对脂质代谢的影响

Abstract
Figure/Table
References (22)
Related Citation (15)

Download: PDF (555 KB) HTML (1 KB)
Export: BibTeX | EndNote (RIS)

Abstract Objective To observe the clinical effects of Gelan Xinning Soft Capsules in the treatment of angina pectoris in coronary heart disease and the influence on lipid metabolism. Methods One hundred and twenty patients with angina pectoris in coronary heart disease hospitalized in Shuguang Hospital Affiliated to Shanghai University of Traditional Chinese Medicine, Xinhua Hospital Affiliated to Shanghai Jiao Tong University, Ninth People's Hospital Affiliated to Shanghai Jiao Tong University, Putuo Central Hospital Affiliated to Shanghai University of Traditional Chinese Medicine from October 2015 to September 2016 were selected and randomly divided into control group (40 cases) and Gelan Xinning group (80 cases) by the ratio of 1∶2. Both groups were treated with conventional western medicine, on basis of which, Gelan Xinning group was treated with Gelan Xinning Soft Capsules, the course was 12 weeks. The efficacy of TCM syndromes, scores of angina pectoris, changes of blood lipid in the two groups were observed. Results The total effective rate of Gelan Xinning group was 78.6%, which was higher than that in the control group (29.4%), the difference was highly statistically significant (P ＜ 0.01). After treatment, the scores of angina pectoris in the two groups were all significantly lower than those before treatment (P ＜ 0.01), and the scores of angina pectoris in the Gelan Xinning group was significantly lower than that in the control group (P ＜ 0.01). After treatment, the levels of total cholesterol (TC), low density lipoprotein cholesterol (LDL-C) in the two groups were all statistically significantly lower than those before treatment (P ＜ 0.05 or P ＜ 0.01), the levels of triglyceride (TG), non-high-density lipoprotein cholesterol (non-HDL-C) in the Gelan Xinning group were significantly lower than those before treatment (P ＜ 0.01), while there were no statistically significant differences of TG, non-HDL-C within the control group before and after treatment (P ＞ 0.05). There were no statistically significant differences of high density lipoprotein cholesterol (HDL-C), apolipoprotein A (ApoA), apolipoprotein B (ApoB) within the two groups before and after treatment (P ＞ 0.05). After treatment, the TG in Gelan Xinning group was lower than that of control group, ApoA was higher than that of control group, the differences were all statistically significant (P ＜ 0.05). Conclusion On basis of conventional treatment, Gelan Xinning Soft Capsules in the treatment of patients with angina pectoris in coronary heart disease can significantly improve the clinical symptoms and regulate the lipid metabolism, and it is safe and effective.

Key words： Coronary heart disease Angina pectoris Gelan Xinning Soft Capsules Lipid metabolism TCM syndromes

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	RUAN Xiaofen WANG Yingjie SHAO Chunlin GAO Junjie CHEN Tiejun XIA Nan WANG Xiaolong

Cite this article:

RUAN Xiaofen WANG Yingjie SHAO Chunlin GAO Junjie CHEN Tiejun XIA Nan WANG Xiaolong. Clinical effects of Gelan Xinning Soft Capsules in the treatment of angina pectoris in coronary heart disease and the influence on lipid metabolism[J]. 中国医药导报, 2017, 14(18): 138-141,152.

URL:

http://www.yiyaodaobao.com.cn/EN/ OR http://www.yiyaodaobao.com.cn/EN/Y2017/V14/I18/138

[1] Wong MC，Zhang DX，Wang HH. Rapid emergence of ath-erosclerosis in Asia：a systematic review of coronary atherosclerotic heart disease epidemiology and implications for prevention and control strategies [J]. Curr Opin Lipidol，2015，26（4）：257-269.
[2] 曹云云，郭瑜林，尹化斌，等.上海市闵行区中老年人群颈动脉粥样硬化现状及危险因素分析[J].中国医药导报，2015，12（6）：26-30.
[3] Masuda D，Yamashita S. Postprandial Hyperlipidemia and Remnant Lipoproteins [J]. J Atheroscler Thromb，2017，24（2）：95-109.
[4] 张秀荣，王海瑞，季旭明.基于中医传承辅助平台分析治疗冠心病方剂组方的规律[J].西部中医药，2016，29（1）：96-100.
[5] 杨戈，王阶，李美华.葛兰心宁软胶囊药物组成对心脑血管作用的临床与实验研究概述[J].中医药学刊，2006，24（4）：614-616.
[6] 颜红兵，马长生，霍勇.临床冠心病诊断与治疗指南[M].北京：人民卫生出版社，2010.
[7] 中华人民共和国卫生部医政司.中国常见心脑血管疾病诊治指南[M].北京：北京科学出版社，2000：59-60.
[8] 郑筱萸.中药新药临床研究指导原则[M].北京：中国医药科技出版社，2002：85-89.
[9] 王冰.黄帝内经[M].北京：中医古籍出版社，2008.
[10] 陈慧，张治祥.《神农本草经》中治疗冠心病的中药统计[J].国医论坛，2016，31（6）：60-62.
[11] 陈敬博.葛兰心宁软胶囊治疗冠状动脉粥样硬化性心脏病不稳定型心绞痛临床观察[J].中医学报，2015，30（4）：598-599.
[12] 陈剑飞，晋军，李佑美.葛兰心宁对不稳定型心绞痛患者冠状动脉介入治疗疗效的影响[J].中华老年医学杂志，2012，31（11）：1017-1018.
[13] 路广秀，包立道，张芳.葛根素对高脂血症患者靶器官功能的保护作用[J].中国临床研究，2017，30（2）：165-167.
[14] 朱黎霞，王利胜，张英丰.丹参总酚酸、山楂总黄酮组分配伍对高脂血症大鼠血脂、超氧化物歧化酶及丙二醛的影响[J].中国医药导报，2014，11（20）：9-12.
[15] 阎博，吴芳，刘海静，等.HPLC-ELSD法测定葛兰心宁软胶囊中绞股蓝皂苷XLIL的含量[J].安徽医药，2015， 19（2）：256-258.
[16] 雷婧，许韩婷，苏洁，等.不同含量绞股蓝皂苷对高脂血症大鼠血脂的影响[J].上海中医药大学学报，2014，28（2）：60-64.
[17] 苏利霄，聂晓敏，周玉杰，等.葛兰心宁软胶囊对非ST段抬高型急性冠状动脉综合征患者介入术后内皮功能的影响[J].中国医药，2013，8（3）：292-294.
[18] 梁姿国，夏丽华.葛兰心宁软胶囊治疗冠心病心绞痛的有效性和安全性[J].实用心脑肺血管病杂志，2014，22（11）：50-51.
[19] 管一平，刘志辉，钱薇.颈动脉、低密度脂蛋白预测冠状动脉粥样硬化性心脏病探讨[J].中国医药导报，2012，9（17）：120-121，124.
[20] 徐嘉，徐岩，张建华，等.血清载脂蛋白B联合非高密度脂蛋白胆固醇对冠心病的预测价值[J].安徽医科大学学报，2016，51（2）：259-262.
[21] 伍世恒，王大伟.复方丹参滴丸与单硝酸异山梨酯缓释片联合用药治疗心绞痛的临床效果[J].成都医学院学报，2016，11（4）：423-426.
[22] Kühnast S，Fiocco M，van der Hoorn JW，et al. Innovative pharmaceutical interventions in cardiovascular disease：Focusing on the contribution of non-HDL-C/LDL-C-lowering versus HDL-C-raising：A systematic review and meta-analysis of relevant preclinical studies and clinical trials [J]. Eur J Pharmacol，2015，763（Pt A）：48-63.